Form 4: Aquestive Therapeutics Director Receives Stock Options
Statement of Changes in Beneficial Ownership
Director John Cochran was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity incentive.
Summary
- Director John Cochran received a grant of 50,500 stock options on June 10, 2026.
- The options have an exercise price of $3.99 per share.
- The grant is subject to a one-year cliff vesting schedule, with 100% of the options vesting on June 10, 2027.
- The options expire on June 10, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
- Standard retention mechanism for board members.
Negatives
- Results in potential future dilution of existing shareholders upon exercise of the options.
Risks
- Market price volatility could impact the value of the options.
- Vesting is contingent upon the director's continuous service with the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an equity grant to a director.
Industry Context
StockSavvy.ai notes that equity grants to board members are a standard corporate governance practice in the biotechnology sector to ensure alignment between leadership and shareholders.
Comparison to Industry Standards
- The use of time-based vesting (one-year cliff) is consistent with standard compensation practices for non-employee directors in small-cap pharmaceutical companies.
- The grant size is typical for board-level equity compensation packages.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director John Cochran authorized several individuals to act as attorneys-in-fact for SEC filing purposes. | 04/16/2026 | Administrative update to facilitate regulatory compliance. |
Stakeholder Impact
- Shareholders: Potential minor dilution upon future exercise of options.
- Director: Increased equity stake in the company.
Next Steps
- Director to remain in service through June 10, 2027, to satisfy vesting requirements.
Key Dates
| Date | Description |
|---|---|
| 04/16/2026 | Date of Power of Attorney execution. |
| 06/10/2026 | Grant date of stock options and earliest transaction date. |
| 06/10/2027 | Vesting date for the 50,500 stock options. |
| 06/10/2036 | Expiration date of the stock options. |
Keywords
Aquestive Therapeutics, AQST, Stock Options, Director Compensation, Insider Transaction, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.